Editas Medicine, Inc. (EDIT): Total Assets
$186.53M
As of 2025-12-31
$237.36M
As of 2026-06-30
-28.7%
3-year compound annual growth
-20.1%
5-year compound annual growth
+2.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $186.53M | -45.4% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $341.59M | -31.6% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $499.15M | -2.9% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $514.32M | -24.1% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $677.48M | +18.3% | 2023-02-22, Balance as of period end |
| 2020-12-31 | $572.60M | +12.5% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $508.88M | +21.1% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $420.39M | +12.6% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $373.26M | +62.9% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $229.18M | +53.4% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $149.36M | n/a | 2017-03-03, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $82.35M | +12.2% |
Compare EDIT, VYGR, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗